In last trading session, Aquestive Therapeutics Inc (NASDAQ:AQST) saw 3.39 million shares changing hands with its beta currently measuring 1.88. Company’s recent per share price level of $2.38 trading at $0.16 or 7.21% at ring of the bell on the day assigns it a market valuation of $236.40M. That closing price of AQST’s stock is at a discount of -143.7% from its 52-week high price of $5.80 and is indicating a premium of 10.92% from its 52-week low price of $2.12.
For Aquestive Therapeutics Inc (AQST), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.11. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.17 in the current quarter.
Aquestive Therapeutics Inc (NASDAQ:AQST) trade information
Upright in the green during last session for gaining 7.21%, in the last five days AQST remained trading in the red while hitting it’s week-highest on Monday, 05/12/25 when the stock touched $2.38 price level, adding 17.93% to its value on the day. Aquestive Therapeutics Inc’s shares saw a change of -33.15% in year-to-date performance and have moved -13.77% in past 5-day. Aquestive Therapeutics Inc (NASDAQ:AQST) showed a performance of -7.39% in past 30-days.
Wall Street analysts have assigned a consensus price target of 7 to the stock, which implies a rise of 66.0% to its current value. Analysts have been projecting 7 as a low price target for the stock while placing it at a high target of 7. It follows that stock’s current price would drop -194.12% in reaching the projected high whereas dropping to the targeted low would mean a loss of -194.12% for stock’s current value.
Aquestive Therapeutics Inc (AQST) estimates and forecasts
This year revenue growth is estimated to fall -20.91% from the last financial year’s standing.
9 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 11.32M for the same. And 9 analysts are in estimates of company making revenue of 12.2M in the next quarter. Company posted 20.1M and 13.54M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 27.90% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -35.73% while estimates for its earnings growth in next 5 years are of 14.57%.
Aquestive Therapeutics Inc (NASDAQ:AQST)’s Major holders
BRATTON CAPITAL MANAGEMENT, L.P. is the top institutional holder at AQST for having 9.81 million shares of worth $25.51 million. And as of 2024-06-30, it was holding 10.7918 of the company’s outstanding shares.
The second largest institutional holder is VR ADVISER, LLC, which was holding about 5.56 million shares on 2024-06-30. The number of shares represents firm’s hold over 6.1109 of outstanding shares, having a total worth of $14.44 million.
On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024, the former fund manager was holding 2.4 shares of worth $5.72 million or 2.42% of the total outstanding shares. The later fund manager was in possession of 1.96 shares on Mar 31, 2025, making its stake of worth around $4.66 million in the company or a holder of 1.97% of company’s stock.
